Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Overview of Paragon 28 Inc
Paragon 28 Inc (FNA) is a specialized medical device company dedicated exclusively to the foot and ankle orthopedic segment. Established in 2010 with a clear mission to blend surgical innovation and quality, the company has built a comprehensive portfolio of surgical solutions targeting complex foot and ankle procedures. Utilizing advanced technologies in orthopedic implants and surgical instrumentation, Paragon 28 aims to set a benchmark in innovation and operational efficiency within the medical device industry.
Mission and Core Values
From its humble beginnings as a small, family-based business, Paragon 28 has consistently maintained its core ideals of innovation, quality, and dedicated service. The company's name is a tribute to its exclusive focus on foot and ankle surgery, with the number '28' symbolizing the anatomical complexity of the human foot. Central to its mission is the drive to advance the science of foot and ankle surgery by integrating diverse surgical philosophies from global thought leaders, ensuring that each surgical solution meets stringent biomechanical and clinical standards.
Comprehensive Product Portfolio
Paragon 28 offers an extensive suite of nearly 80 proprietary surgical product systems. These include a range of orthopedic devices such as plates, plating systems, screws, staples, and nails. These products are meticulously designed to address a variety of foot and ankle procedures including:
- Ankle reconstruction and fixation for complex fractures and musculoskeletal trauma
- Fracture fixation solutions that ensure stability and promote healing
- Procedural instrumentation for deformity corrections, hallux valgus, hammertoe, and flatfoot conditions
- Innovative solutions for specialized conditions such as Charcot foot and progressive collapsing foot deformity
Operational Excellence and Distribution
The company leverages a dedicated and highly trained sales and distribution network to ensure that its advanced orthopedic devices reach a wide network of surgical centers and hospitals, primarily within the United States. This customer-centric approach, combined with efficient operational practices, allows Paragon 28 to address the dual challenges of increasing pricing pressures and reimbursement complexities within the healthcare sector.
Competitive Position and Industry Impact
Operating within the dynamic and competitive landscape of orthopedics, Paragon 28 has distinguished itself through its unwavering focus on the foot and ankle segment. By prioritizing innovation and tailoring its product offerings to meet the precise needs of both patients and surgeons, the company has established a strong operational niche. Its strategy of blending global surgical insights with a rigorous quality framework enables it to create products that are not only clinically relevant but also easily reproducible in diverse surgical settings. This distinctive positioning highlights the company’s commitment to improving patient outcomes while maintaining operational efficiency.
Strategy and Business Model
Paragon 28's business model is anchored in its commitment to three primary pillars:
- Creation and Innovation: Investing in research and development to refine surgical techniques and develop devices that address specific clinical challenges in the foot and ankle spectrum.
- Focused Service: Establishing a robust distribution network that ensures timely delivery and superior customer service, which is critical for high-stakes surgical environments.
- Efficient Practices: Implementing operational efficiencies to navigate challenges related to evolving reimbursement frameworks and pricing pressures, thereby sustaining a cycle of quality and innovation.
Expertise and Authoritativeness
The company's process of integrating varied surgical philosophies into its product design reflects deep industry expertise. Paragon 28’s commitment to ongoing research and development, along with its emphasis on user-friendly yet technologically advanced products, positions it as a trusted name among orthopedic surgeons. The company’s continuous efforts in refining its product systems set a high standard of care in the specialized field of foot and ankle surgery.
Understanding the Technology and Innovation
In the realm of medical devices, technological innovation is crucial. Paragon 28 harnesses cutting-edge manufacturing techniques and research-driven insights to build devices that enhance surgical precision and reliability. This detailed approach ensures that each product not only conforms to current clinical requirements but also anticipates the nuanced challenges surgeons face during delicate procedures. The application of advanced orthopedic implant technologies and state-of-the-art design principles underscores the company’s commitment to facilitating optimal patient outcomes.
Market Significance and Industry Relevance
Although Paragon 28 operates within a specialized niche of the orthopedic implant market, the company’s influence is profound due to its unwavering focus on quality, innovation, and customer service. Its strategic approach, combined with a suite of versatile surgical solutions, effectively addresses critical gaps in the foot and ankle surgical procedural space. This specialization allows the company to serve a targeted customer base that includes orthopedic surgeons, hospitals, and outpatient surgical centers, all of which rely on dependable and innovative surgical solutions to improve patient care.
Conclusion
In summary, Paragon 28 Inc stands as a comprehensive, innovation-driven entity in the orthopedic medical device arena. Its focused mission, extensive product portfolio, and commitment to blending global surgical insights with efficient, reliable service have positioned it as a pivotal player in addressing the challenges of foot and ankle surgery. Through its attention to detail in both product development and operational execution, Paragon 28 offers a detailed case study of how concentrated expertise can drive significant advancements in medical technology.
Paragon 28, Inc. (NYSE: FNA) reported its financial results for Q4 and full year 2022, showcasing a strong revenue performance.
Q4 consolidated net revenue reached $51.5 million, marking a 20.4% increase. For the full year, consolidated net revenue totaled $181.4 million, up 23%. U.S. revenue for Q4 was $45.3 million, contributing to a 22% annual growth rate. The gross margin remained robust at 82% for both Q4 and the entire year.
However, the company faced a net loss of $38.8 million for Q4, up from a loss of $6.2 million in the prior year, and an annual loss of $67.3 million.
Looking ahead, Paragon 28 anticipates net revenue of $214-$218 million for 2023, indicating an 18%-20% growth.
Paragon 28, a medical device company focused on the foot and ankle orthopedic market, announced that Chairman and CEO Albert DaCosta and CFO Steve Deitsch will present at two investor conferences. The first event is the CG 2023 Musculoskeletal Conference on March 7, 2023, at 4:00 PM ET, and the second is the 22nd Annual Needham Virtual Healthcare Conference on April 19, 2023, at 11:00 AM ET. Live and archived webcasts will be available on the company’s website. Paragon 28 aims to improve patient outcomes through innovative orthopedic solutions for various foot and ankle conditions.
Paragon 28, Inc. (NYSE: FNA) has completed the sale of an additional 975,000 shares following an underwritten public offering of 6,500,000 shares at $17.00 per share. The total proceeds from the offering approximated $73.3 million, with 562,500 shares sold by Paragon and 412,500 shares by selling securityholders. The funds will primarily support working capital, capital expenditures, and other corporate purposes, potentially including acquisitions. The public offering was conducted under an SEC registration statement filed in November 2022.
Paragon 28, Inc. (NYSE: FNA), a leader in the foot and ankle orthopedic market, will release its financial results for Q4 and FY 2022 after market close on March 2, 2023. A conference call will follow at 4:30 p.m. ET, available for investors by dialing (844-200-6205) domestically and (929-526-1599) internationally, with conference ID 798665. The call will also be accessible via webcast on the company's investor website. Established in Englewood, Colo., Paragon 28 focuses on innovative orthopedic solutions aimed at improving patient outcomes in foot and ankle conditions.
Paragon 28, Inc. (NYSE: FNA) announced a public offering of 6,500,000 shares of its common stock, priced at
Paragon 28, Inc. (NYSE: FNA) has announced a proposed underwritten public offering of 6,500,000 shares of its common stock, with 3,750,000 shares from Paragon and 2,750,000 shares from selling securityholders. Additionally, underwriters may purchase 975,000 shares under a 30-day option. Proceeds will primarily support working capital and corporate needs, with possibilities for product investments. However, Paragon will not benefit from the sale of shares by selling securityholders. BofA Securities and Piper Sandler & Co. lead the offering, which is subject to market conditions.
Paragon 28, Inc. (NYSE: FNA) has announced its preliminary unaudited revenue for Q4 and the full year of 2022. Q4 revenue is projected between $51.2 million and $51.5 million, marking a growth of approximately 20% year-over-year, despite foreign currency challenges impacting growth by 1.6 percentage points. For the full year, net revenue is expected to be between $181.0 million and $181.3 million, reflecting a growth of about 23.0% compared to 2021. The company plans to release its 2023 financial guidance later in the quarter.
Paragon 28, Inc. (NYSE: FNA), a leader in the medical device sector focusing on the foot and ankle orthopedic market, will have CEO Albert DaCosta and CFO Steve Deitsch participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference. This event is scheduled for Thursday, December 1, 2022, at 8:30 a.m. Eastern Time. A live webcast and archived recording will be accessible on the company's investor relations website.
Paragon 28 is committed to improving patient outcomes through innovative orthopedic solutions.
Paragon 28, Inc. (NYSE: FNA) reported a record net revenue of $46.0 million for Q3 2022, marking a 28% increase from the previous year. U.S. revenue reached $40.0 million, up 25%, driven by improved sales productivity and new product launches. International revenue also set a record at $6.0 million, growing 52%. Despite foreign currency headwinds impacting revenue by $0.8 million, the company raised its 2022 net revenue guidance to $179.5 million, reflecting a 22% growth. However, net loss expanded to $9.7 million, contributing to a negative adjusted EBITDA of $2.7 million.
Paragon 28, Inc. (NYSE: FNA), a leading medical device company focused on foot and ankle orthopedics, will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss the results. Investors can participate by dialing (844-200-6205) or (929-526-1599) internationally, using conference ID: 703484. The call will be available for replay for 90 days on the company’s website.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28 Inc specialize in?
What types of products does Paragon 28 offer?
How does Paragon 28 generate revenue?
What are the core values of Paragon 28 Inc?
How does Paragon 28 maintain industry expertise?
What distinguishes Paragon 28 in the competitive orthopedic market?
Who are the primary customers of Paragon 28?
How does Paragon 28 address the challenges in the healthcare market?
